Tier 2 — strong

A double-blind, placebo-controlled, randomised, clinical study on the effectiveness of collagen peptide on osteoarthritis

Suresh Kumar, Fumihito Sugihara, Keiji Suzuki, Naoki Inoue, Sriraam Venkateswarathirukumara
Journal of the Science of Food and Agriculture 2015 95(4):702–707

Bibliography

PubMed
PMID 24852756
DOI
10.1002/jsfa.6752
Competing interests
Lead author was affiliated with Nitta Gelatin India Ltd, a collagen ingredient manufacturer; formulation-specific industry research.

Study snapshot

DesignRandomized double-blind placebo-controlled clinical study.
ModelPeople with diagnosed knee osteoarthritis.
SampleMultiple randomized pork, bovine and placebo groups; verify full text for exact denominators.
InterventionSelected porcine-skin collagen peptides or bovine-bone collagen peptides versus placebo.
Duration13 weeks
EndpointsWOMAC; VAS pain; Quality of life; Safety

What the study showed, in plain terms

A randomized study reported better WOMAC, VAS pain and quality-of-life scores with selected pork-skin and bovine-bone collagen peptides versus placebo after 13 weeks. Because manufacturer researchers were involved and formulations differed, this does not establish that every collagen product performs identically.

Key findings

Both active collagen groups showed reported symptom improvements versus placebo at the final visit (reported p<0.01).

What this study can and cannot tell us

Manufacturer-affiliated study of specific preparations. Short duration; improvements in symptoms cannot be equated with cartilage regrowth or reduced need for joint replacement.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology